Bristol-Myers Squibb Appoints Giovanni Caforio, M.D., Chief Executive Officer, Effective May 5; Lamberto Andreotti to Become ...
January 20 2015 - 4:30PM
Business Wire
Bristol-Myers Squibb Company (NYSE:BMY) today announced a number
of leadership changes approved by its board of directors and
effective at the close of the annual Shareholders’ Meeting on May
5.
Giovanni Caforio, M.D. (Photo: Business
Wire)
- Giovanni Caforio, M.D., 50, will become
chief executive officer of the company.
- Lamberto Andreotti, 64, will become
executive chairman of the board of directors on May 5 and will
continue to serve as chairman after his retirement on August
3.
- James M. Cornelius, 71, has chosen not
to stand for re-election as non-executive chairman and will retire
from the board.
- Togo D. West, Jr., 72, will become the
lead independent director on the company’s board.
“I want to thank Jim Cornelius for his many years at BMS,”
Andreotti said. “Through his leadership and strategic vision, Jim
oversaw the successful transformation of our company. As CEO of
Bristol-Myers Squibb, I am grateful to have had his guidance as a
mentor and a friend.”
“I also want to express my excitement that Giovanni has been
appointed to succeed me as CEO,” Andreotti said. “I have a high
level of confidence in Giovanni that is shared by everyone who has
seen him consistently and successfully drive performance. He has an
unmatched breadth and depth of experience. From his start in a
medical role to his experience as a general manager to his roles as
chief commercial officer and chief operating officer, Giovanni has
demonstrated a unique ability to work across the organization to
bring innovative medicines to patients.”
“I am honored to have the privilege to lead this great company,”
Caforio said. “Lamberto has led the successful transformation of
BMS from a broad-based health care company to a Diversified
Specialty BioPharma leader with his passion for our business, our
people and, most importantly, our patients. I look forward to
working with our very talented team of people at BMS to build on
what we’ve accomplished, to deliver on the promise of our
innovative portfolio and to continue to make a real difference for
our patients.”
“This is an extraordinary company of talented people with
incomparable passion and dedication to helping patients,” Cornelius
said. “With Giovanni’s appointment as CEO and Lamberto’s
appointment as chairman, we ensure the continuation of both the
leadership and strategy that have made BMS successful.”
Caforio brings a broad range of experience to his role as CEO.
Through ever-expanding roles, Caforio has made significant
contributions to improving the company’s strategic focus and
operational performance. He helped build the company’s leadership
in immuno-oncology through his roles in U.S. and Global Oncology.
As chief commercial officer and chief operating officer he led the
transformation of the company’s global commercial organization into
one uniquely designed to be able to differentially invest in the
most important opportunities. As a member of the company’s Senior
Management Team since 2011 and the company’s board of directors
since 2014, Caforio has been integral in shaping the company’s
successful transformation to a Diversified Specialty BioPharma
company. A trained physician, Caforio began his career in Medical
Affairs at Abbott Laboratories. He joined Bristol-Myers Squibb in
2000 as vice president and general manager, Italy. Caforio earned
his M.D. from the University of Rome prior to joining the
pharmaceutical industry.
Andreotti joined Bristol-Myers Squibb in 1998 as vice president
and general manager, Italy and European Oncology. He held a number
of roles of increasing responsibility and was elected to the board
of directors in March 2009. He became CEO in May 2010. He also sits
on the board of directors of E. I. du Pont de Nemours and
Company.
Cornelius has been non-executive chairman since May 2010. He
served as chairman and chief executive officer from February 2008
to May 2010 and served as our chief executive officer from
September 2006 to February 2008. Cornelius is the non-executive
chairman of the board of directors of Mead Johnson Nutrition
Company.
About Bristol-Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical company whose
mission is to discover, develop and deliver innovative medicines
that help patients prevail over serious diseases. For more
information, please visit www.bms.com or follow us on Twitter at
http://twitter.com/bmsnews.
Photos/Multimedia Gallery Available:
http://www.businesswire.com/multimedia/home/20150120006656/en/
Bristol-Myers SquibbMedia:Jennifer Fron Mauer,
609-252-6579jennifer.mauer@bms.comorKen Dominski,
609-252-5251ken.dominski@bms.comorInvestors:John Elicker,
609-252-4611john.elicker@bms.comorRanya Dajani,
609-252-5330ranya.dajani@bms.com
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Apr 2023 to Apr 2024